TuHURA Biosciences (NASDAQ:HURA) Raised to “Hold” at Wall Street Zen

TuHURA Biosciences (NASDAQ:HURA) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

HURA has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, TuHURA Biosciences currently has an average rating of “Hold” and a consensus price target of $9.00.

TuHURA Biosciences Stock Performance

HURA stock opened at $1.79 on Monday. The firm has a 50 day moving average price of $1.34 and a 200-day moving average price of $1.64. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $4.44. The firm has a market capitalization of $108.69 million, a price-to-earnings ratio of -3.58 and a beta of -0.30.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02.

Hedge Funds Weigh In On TuHURA Biosciences

A number of hedge funds have recently added to or reduced their stakes in HURA. Bank of America Corp DE bought a new position in TuHURA Biosciences in the 4th quarter valued at approximately $59,000. Jane Street Group LLC purchased a new position in shares of TuHURA Biosciences in the first quarter worth $69,000. Geode Capital Management LLC raised its stake in shares of TuHURA Biosciences by 111.4% in the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after purchasing an additional 307,260 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of TuHURA Biosciences during the second quarter valued at $29,000. Finally, JPMorgan Chase & Co. bought a new position in shares of TuHURA Biosciences during the second quarter valued at $27,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.